Testing Effect Homogeneity and Confounding in High-Dimensional Experimental and Observational Studies
高维实验与观察性研究中的效应同质性及混杂检验AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接检验跨研究处理效应,并明确扩展至依赖平行趋势的面板双重差分。
高维实验与观察性研究中的效应同质性及混杂检验AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We propose a framework for testing the homogeneity of conditional average treatment effects (CATEs) across multiple experimental and observational studies. Our approach leverages multiple randomized trials to assess whether treatment effects vary with unobserved heterogeneity that differs across trials: if CATEs are homogeneous, this indicates the absence of interactions between treatment and unobservables in the mean effect. Comparing CATEs between experimental and observational data further allows evaluation of potential confounding: if the estimands coincide, there is no unobserved confounding; if they differ, deviations may arise from unobserved confounding, effect heterogeneity, or both. We extend the framework to settings with alternative identification strategies, namely instrumental variable settings and panel data with parallel trends assumptions based on differences in differences, where effects are identified only locally for subpopulations such as compliers or treated units. In these contexts, testing homogeneity is useful for assessing whether local effects can be extrapolated to the total population. We suggest a test based on double machine learning that accommodates high-dimensional covariates in a data-driven way and investigate its finite-sample performance through a simulation study. Finally, we apply the test to the International Stroke Trial (IST), a large multi-country randomized controlled trial in patients with acute ischaemic stroke that evaluated whether early treatment with aspirin altered subsequent clinical outcomes. Our methodology provides a flexible tool for both validating identification assumptions and understanding the generalizability of estimated treatment effects.